« Return to News | R&D Trends

Immunocore, GlaxoSmithKline sign research and licensing agreement

Wednesday, July 10, 2013 12:26 PM

Immunocore, an Oxford-based biotechnology company developing novel biological drugs called ImmTACs to treat cancer and viral disease, has entered into a partnership with GlaxoSmithKline for multiple novel targets not addressable using antibody-based technologies. This is Immunocore's second major partnership this year.

Immunocore will receive up to $182 million in preclinical milestone payments. In addition, for each product that reaches the market, up to $256 million is due in milestones, plus royalties.

Immunocore will be responsible for preclinical development and initial trials in patients, and GSK will be responsible for the remaining development and commercialization of the products.

Immunocore has created a platform of bi-specific biological drugs, called ImmTACs (Immune mobilizing mTCR Against Cancer), which exploit the power of T Cell Receptors (TCRs) to recognize intracellular changes that occur during cancer or viral infection. This recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognize changes on the surface of cells, and provides the ability to develop targeted therapies for cancers.

The ImmTAC drug IMCgp100, for the treatment of melanoma, is currently in phase I/II trials in the U.K. and U.S.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.